Recent News

• 09.04.2025 - Wells Fargo Healthcare Conference
• 09.04.2025 - Wells Fargo Healthcare Conference
• 09.03.2025 - Cantor Global Healthcare Conference
• 09.03.2025 - Cantor Global Healthcare Conference
• 09.03.2025 - Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
• 09.03.2025 - Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
• 08.06.2025 - Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)
• 08.06.2025 - Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)

Recent Filings

• 08.29.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.06.2025 - EX-99.1 EX-99.1
• 08.06.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.06.2025 - 8-K Current report
• 06.17.2025 - 8-K Current report
• 06.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.16.2025 - 4 Statement of changes in beneficial ownership of securities